SYK Ausblick überarbeitet mit reduziertem Kursziel, aber neutraler Bewertung

What happened: On March 23, 2026, Truist lowered its price target on Synchrony Financial (SYF) from $84 to $71, maintaining a Hold rating. A week earlier, UBS revised its outlook on Stryker Corporation (SYK), reducing the price target from $400 to $380 while keeping a Neutral rating. Meanwhile, Stryker Corp. (SYK) announced a Q1 income advance, reporting earnings of $745 million, or $1.93 per share, compared to $654 million, or $1.69 per share, in the same period last year.

Market impact: The revisions in price targets for SYF and SYK reflect analyst sentiment shifts, potentially driving valuation repricing in the financial services and medical technology sectors. The earnings beat by SYK could influence investor sentiment towards the broader medical device industry.

What to watch next: Investors should closely monitor SYF's Q1 earnings release, scheduled for April 25, 2026, to gauge the company's performance and potential impact on Truist's revised price target. Additionally, the upcoming Q2 earnings from SYK, expected on May 10, 2026, will provide further insight into the company's growth trajectory following its Q1 income advance.